Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Whiting

Showing results (241-250 of 244) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 244 results.
Pancreas|October 2, 2023
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic AdenocarcinomaAndrew L Coveler, Venu G Pillarisetty, Wui-Jin Koh, et al.
Cancer Research Communications|March 29, 2024
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid TumorsMark Yarchoan, John D Powderly, Bruno R Bastos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
Cancer Discovery|January 21, 2026
Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal CancerWilliam C H Cross, Salpie Nowinski, George D Cresswell, et al.
Pageof 25

Showing results (241-250 of 244) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 244 results.
Pancreas|October 2, 2023
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic AdenocarcinomaAndrew L Coveler, Venu G Pillarisetty, Wui-Jin Koh, et al.
Cancer Research Communications|March 29, 2024
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid TumorsMark Yarchoan, John D Powderly, Bruno R Bastos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2022
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I TrialFunda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, et al.
Cancer Discovery|January 21, 2026
Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal CancerWilliam C H Cross, Salpie Nowinski, George D Cresswell, et al.
Pageof 25